<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Defining Organoids: Exploring Their True Characteristics and Practical Uses

The use of more clinically relevant preclinical models can help to reduce anticancer drug attrition rates by providing a better understanding of the safety, efficacy, and mechanism of a drug candidate, which can help inform downstream decisions.

This blog post explores the value of adult stem cell-derived 3D in vitro tumor organoids in drug discovery, particularly in identifying anticancer agents with improved translational potential, as highlighted in recent peer-reviewed publications.

What Is an Organoid?

The term "organoid" has previously been used when referring to groups of cells that create 3D structures when grown without attachment substrates.

Today, it specifically refers to a 3D structure with cells that establish or retain the identity of the organ/tissue being modeled, both stem cells and their progeny. Organoids are typically derived from either pluripotent stem cells (PSCs), i.e., embryonic stem cells or induced PSCs, or multipotent organ-specific adult stem cells (ASCs).

Organoids are composed of multiple cell types found in the specific parental organ/tissue (which can be either healthy or diseased, such as tumor tissue), exhibit some aspect of its functional properties, and self-organize following the same intrinsic principles as the original organ/tissue.

Organoids are distinct from other 3D models. For example, spheroids are created from a single cell type or a mixture of cells and can originate from stem cells, primary cells, immortalized cell lines, or human tissue. They are also composed of various layers of cells, which can result in heterogeneity, including cells that are oxygenated, hypoxic, proliferating, nonproliferating, and/or necrotic.

Key Differences Between PSC- and ASC-Derived Organoids

PSC organoids are often used to model organogenesis. However, the protocols to generate them are more time consuming and complex compared to those for developing ASC-based organoids (see our previous blog post for a more in-depth discussion).

In short, ASC-derived organoids circumvent some of the steps required for PSC organoids because they are established from tissue-specific stem cell populations using optimized protocols.

Robust protocols use optimized conditions to preserve the stem cell self-renewing and differentiating potential of purified single ASCs or tissue-specific microstructures. The resulting organoids faithfully recapitulate the phenotypic and genetic features of their original tissue.

Based on data from published studies (for example, see here, here and here), ASC-derived organoids represent the first clinically relevant 3D in vitro model to show the following:

  • Genomic and phenotypic stability in long-term culture and after cryopreservation,
  • Ease of scalability relative to in vivo models, and
  • Clinical predictivity.

Furthermore, their genomic and phenotypic stability after cryopreservation has allowed the development of living organoid biobanks (such as OrganoidBase™) containing models covering multiple solid cancer types and enabled clinical trials as surrogate subjects in vivo. This approach is the equivalent of a clinical trial but carried out in a dish, expediting drug development, and reducing the high attrition rate of oncology candidates.

The Value of ASC-Derived Organoids: Scalability, Reproducibility, and Clinical Relevance

Adult stem cell-derived in vitro tumor organoids are powerful predictive preclinical models for cancer drug discovery and development largely due to characteristics that enable their scalability, reliability, and high patient predictivity. Below are summaries of two recent studies that highlight the power and potential of tumor organoids for cancer drug discovery and development.

In a study published in PLOS ONE, scientists from Crown Bioscience reported on the development of a biobank of patient-derived-xenograft organoids (PDXOs) from a PDX library. The goal was to assess the biological equivalency or interchangeability between the PDXs and corresponding PDXOs and compare their pharmacological responses.

The scientists tested more than 550 matched in vitro and in vivo models representing a variety of cancer types. Overall, the biological equivalency between the two types of models was confirmed using extensive genomic and histopathological characterization. The in vitro PDXO and in vivo PDX pharmacology had high correlation.

The biobank was also successfully used for high-throughput “matrix” screening for both lead compounds and indications, immune cell co-cultures for immuno-therapies, and genetic engineering for in vitro/in vivo imaging. Overall, it was concluded:

“this large biobank of >550 matched pairs of PDXs/PDXOs across different cancers could become a powerful tool for the future of cancer drug discovery.”

A second study in Nature Cancer reported preclinical data on a bispecific antibody that was shown to prevent the onset of metastasis and slow the growth of primary tumors in experimental models.

A large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank (developed using optimized protocols) and paired healthy colonic mucosa samples was conducted.

Overall, 500+ bAbs generated against Wingless-related integration site (WNT) and receptor tyrosine kinase targets were functionally evaluated by high-content imaging to capture the complexity of PDO responses. This enabled discriminating antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism-of-action studies that enabled selection of optimally performing antibodies.

This strategy resulted in identifying MCLA-158, a bAb that triggers epidermal growth factor receptor degradation in leucine-rich repeat-containing G-protein-coupled receptor 5-positive (LGR5+) cancer stem cells but with minimal toxicity toward healthy LGR5+ colon stem cells.

MCLA-158 therapeutic properties (i.e., growth inhibition of KRAS-mutant colorectal cancers, blockade of metastasis initiation, and suppression of tumor outgrowth) were confirmed in matched PDX models for several epithelial cancer types.

This groundbreaking work confirmed the power of 3D in vitro tumor organoids by shrinking the time between initial discovery to clinical trials to approximately five years.

Conclusion

Organoids are becoming increasingly popular in cancer drug discovery and development since they offer a balance between scalability and clinical-predictivity compared to in vivo and other in vitro models. These models accurately reflect the genomic, morphological, and pathophysiological features of the original tumor. Overall, organoids have great potential for improving the efficiency and success of cancer drug discovery, and are a promising avenue for future research.

Visit Crown Bioscience’s Organoids for Oncology Drug Development site to learn more about how we help researchers advance their drug discovery and development programs.


Related Posts